Philipp le Coutre,
Oliver G. Ottmann,
Francis Giles,
Dong-Wook Kim,
Jorge Cortes,
Norbert Gattermann,
Jane F. Apperley,
Richard A. Larson,
Elisabetta Abruzzese,
Stephen G. O'Brien,
Kazimierz Kuliczkowski,
Andreas Hochhaus,
Francois-Xavier Mahon,
Giuseppe Saglio,
Marco Gobbi,
Yok-Lam Kwong,
Michele Baccarani,
Timothy Hughes,
Giovanni Martinelli,
Jerald P. Radich,
Ming Zheng,
Yaping Shou,
Hagop Kantarjian,
- Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. le Coutre, P., Ottmann, O.G., Giles, F., Kim, D.W., Cortes, J., Gattermann, N., Apperley, J.F., Larson, R.A., Abruzzese, E., O'Brien, S.G., Kuliczkowski, K., Hochhaus, A., Mahon, F.X., Saglio, G., Gobbi, M., Kwong, Y.L., Baccarani, M., Hughes, T., Martinelli, G., Radich, J.P., Zheng, M., Shou, Y., Kantarjian, H. Blood (2008)